PDF(Pubmed)
Abstract：
BACKGROUND: In the U.S., overdose deaths and substance treatment admissions related to methamphetamine are rising. This study aims to measure and compare U.S. temporal trends in methamphetamine-involved psychiatric hospitalizations.
METHODS: We conducted a population-based, trend analysis of U.S. psychiatric hospitalizations and calculated quarterly (Q) rates per 100,000 population of substance-involved psychiatric hospitalizations. We assessed U.S. regional quarterly percentage hospitalization rate changes using Joinpoint regression.
RESULTS: From Q4 2015-Q4 2019, there were 963,202 psychiatric hospitalizations, 50,223 (5.2 %) involved methamphetamine and 102,877 (10.7 %) involved opioids and/or cocaine without methamphetamine. Methamphetamine-involved psychiatric hospitalization rates increased by 68.0 %, psychiatric hospitalizations rates involving opioid and/or cocaine without methamphetamine decreased by 22 %, while nonsubstance-involved psychiatric hospitalizations rates remained unchanged. The largest significant increases in methamphetamine-involved psychiatric hospitalization rates were among people >61 years old, males, and Midwesterners. Methamphetamine-involved psychiatric hospitalization rates doubled among Black patients. The largest average percent increase among methamphetamine-involved psychiatric hospitalizations was 10.2 % from Q4 2015-Q2 2017 in the Midwest.
CONCLUSIONS: Most psychiatric hospitalizations did not involve substances. Methamphetamine-involved psychiatric hospitalizations greatly increased while opioid-involved psychiatric hospitalizations decreased, but involved more total encounters. Greater access to harm reduction services, contingency management programs, and mental health services is urgently needed.
METHODS: We conducted a population-based, trend analysis of U.S. psychiatric hospitalizations and calculated quarterly (Q) rates per 100,000 population of substance-involved psychiatric hospitalizations. We assessed U.S. regional quarterly percentage hospitalization rate changes using Joinpoint regression.
RESULTS: From Q4 2015-Q4 2019, there were 963,202 psychiatric hospitalizations, 50,223 (5.2 %) involved methamphetamine and 102,877 (10.7 %) involved opioids and/or cocaine without methamphetamine. Methamphetamine-involved psychiatric hospitalization rates increased by 68.0 %, psychiatric hospitalizations rates involving opioid and/or cocaine without methamphetamine decreased by 22 %, while nonsubstance-involved psychiatric hospitalizations rates remained unchanged. The largest significant increases in methamphetamine-involved psychiatric hospitalization rates were among people >61 years old, males, and Midwesterners. Methamphetamine-involved psychiatric hospitalization rates doubled among Black patients. The largest average percent increase among methamphetamine-involved psychiatric hospitalizations was 10.2 % from Q4 2015-Q2 2017 in the Midwest.
CONCLUSIONS: Most psychiatric hospitalizations did not involve substances. Methamphetamine-involved psychiatric hospitalizations greatly increased while opioid-involved psychiatric hospitalizations decreased, but involved more total encounters. Greater access to harm reduction services, contingency management programs, and mental health services is urgently needed.
摘要：
背景：在美国，与甲基苯丙胺相关的过量死亡和药物治疗入院人数正在上升。这项研究旨在测量和比较美国与甲基苯丙胺有关的精神病住院的时间趋势。
方法：我们以人群为基础，美国精神病住院率的趋势分析,并计算出每100,000名涉及物质的精神病住院患者的季度(Q)率.我们使用Joinpoint回归评估了美国地区季度住院率百分比变化。
结果：从2015年第四季度到2019年第四季度，有963,202例精神病住院，50,223（5.2％）涉及甲基苯丙胺，102,877（10.7％）涉及阿片类药物和/或可卡因，不含甲基苯丙胺。涉及甲基苯丙胺的精神病住院率增加了68.0%,涉及阿片类药物和/或可卡因而不含甲基苯丙胺的精神病住院率下降了22％，而非物质相关的精神病住院率保持不变。与甲基苯丙胺有关的精神病住院率的最大显着增加是在61岁以上的人群中，男性,和中西部人。在黑人患者中，涉及甲基苯丙胺的精神病住院率翻了一番。在中西部地区，与甲基苯丙胺有关的精神病住院治疗的平均增幅最大，为2015年第四季度至2017年第二季度的10.2％。
结论：大多数精神病住院不涉及药物。涉及甲基苯丙胺的精神病住院治疗大大增加，而涉及阿片类药物的精神病住院治疗减少，但涉及更多的接触。获得更多减少伤害服务的机会，应急管理计划，迫切需要精神卫生服务。
方法：我们以人群为基础，美国精神病住院率的趋势分析,并计算出每100,000名涉及物质的精神病住院患者的季度(Q)率.我们使用Joinpoint回归评估了美国地区季度住院率百分比变化。
结果：从2015年第四季度到2019年第四季度，有963,202例精神病住院，50,223（5.2％）涉及甲基苯丙胺，102,877（10.7％）涉及阿片类药物和/或可卡因，不含甲基苯丙胺。涉及甲基苯丙胺的精神病住院率增加了68.0%,涉及阿片类药物和/或可卡因而不含甲基苯丙胺的精神病住院率下降了22％，而非物质相关的精神病住院率保持不变。与甲基苯丙胺有关的精神病住院率的最大显着增加是在61岁以上的人群中，男性,和中西部人。在黑人患者中，涉及甲基苯丙胺的精神病住院率翻了一番。在中西部地区，与甲基苯丙胺有关的精神病住院治疗的平均增幅最大，为2015年第四季度至2017年第二季度的10.2％。
结论：大多数精神病住院不涉及药物。涉及甲基苯丙胺的精神病住院治疗大大增加，而涉及阿片类药物的精神病住院治疗减少，但涉及更多的接触。获得更多减少伤害服务的机会，应急管理计划，迫切需要精神卫生服务。
